Literature DB >> 16519392

Median nerve palsy after operative treatment of olecranon fracture.

Ekamol Thumroj1, Surut Jianmongkol, Jureerut Thammaroj.   

Abstract

Olecranon fracture is not an uncommon fracture in clinical practice. Simple olecranon fracture usually heals quite well without any types of iatrogenic complications. Despite close proximity of the fracture to the nerve, median nerve palsy after operative treatment of olecranon fracture is a rare complication. To the authors' knowledge, this complication has not been previously reported in the Thai or English literature. The authors present a patient who had median nerve palsy after tension-band wiring for olecranon fixation. Intraoperative finding revealed that the median nerve was injured by the tip of K-wire. While this complication is uncommon on a per-person basis, it may results in serious complication, such as nerve palsy or limb ischemia. Orthopedic surgeons must remain vigilant with regard to any type of internal fixation in the upper extremity because the risk of neurovascular injury is high.

Entities:  

Mesh:

Year:  2005        PMID: 16519392

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  3 in total

1.  Repair of comminuted (Mayo type IIB) olecranon fracture using Ethi-bond 5 sutures without metallic implants: A novel technique.

Authors:  Sheng Xu; Heng An Lin; Merng Koon Wong
Journal:  J Orthop       Date:  2019-03-12

2.  Tension band wiring in olecranon fractures: the myth of technical simplicity and osteosynthetical perfection.

Authors:  Marco M Schneider; Tobias E Nowak; Leonard Bastian; Jan C Katthagen; Jörg Isenberg; Pol M Rommens; Lars P Müller; Klaus J Burkhart
Journal:  Int Orthop       Date:  2013-12-12       Impact factor: 3.075

3.  Malpositioned olecranon fracture tension-band wiring results in proximal radioulnar synostosis.

Authors:  Lukas Willinger; Martin Lucke; Moritz Crönlein; Gunther H Sandmann; Peter Biberthaler; Sebastian Siebenlist
Journal:  Eur J Med Res       Date:  2015-10-29       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.